Who We Help
Since 2009, Voices of Hope has donated over $600,000 dollars to cancer research. From 2009 to 2011, Voices of Hope supported the Belfer Institute for Applied Cancer Sciences at The Dana-Farber Cancer Institute. In 2013, Voices of Hope began supporting the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center.
Donations to Date
- 2009 – $17,000
- 2010 – $48,000
- 2011 – $70,000
- 2012 – $55,000
- 2013 – $60,000
- 2014 – $62,000
- 2015 – $75,000
- 2016 – $113,500
- 2017 – $100,000
The Henri and Belinda Termeer Center for Targeted Therapies offers new hope to patients and their families at the Massachusetts General Hospital Cancer Center and beyond, as the center defines the future of cancer therapy.
Led by Keith T. Flaherty, MD, a renowned expert in personalized cancer medicine and melanoma specialist, the Termeer Center offers a comprehensive, translational research program to speed the discovery and delivery of new targeted therapies to patients with early and advanced stage cancers.
The Termeer Center brings together cutting-edge research resources and provides a foundation for
collaborations among physicians and investigators from a broad spectrum of biomedical disciplines, resulting in a rapidly expanding arsenal of weapons against cancer. Leading specialists from the Cancer Center’s 23 disease centers participate in the Termeer Center by enrolling their patients in its fast-growing portfolio of Phase I, Phase II, and Phase III clinical trials.
The cycle of discovery is swift and efficient, with newly identified genetic abnormalities revealing new information about cancer pathways and creating novel investigative possibilities not only for Mass General researchers, but for scientific collaborators around the world. The Termeer Center’s goal is to cut the average time for drug development from ten years to five years and, with more clinical trials, improve access to therapy for patients.
With hundreds of new anti-cancer therapies now in the development pipeline and countless patients waiting for targeted drugs that match their individual tumors, the Termeer Center’s work is vital and timely. To learn more about the Termeer Center, please visit their website.